1. Siegel, R. L., K. D. Miller, and A. Jemal. 2015. Cancer statistics, 2015. CA Can J Clin 65:5–29.
2. Punnen, S., and M. R. Cooperberg. 2013. The epidemiology of high-risk prostate cancer. Curr. Opin. Urol.23:331–336.
3. Mohler, J. L. 2010. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J. Natl. Compr. Canc. Netw. 8:145.
4. Horwitz, E. M., K. Bae, G. E. Hanks, A. Porter, D. J. Grignon, H. D. Brereton, et al. 2008. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26:2497–2504.
5. Bolla, M., T. M. de Reijke, G. Van Tienhoven, A. C. Van den Bergh, J. Oddens, P. M. Poortmans, et al. 2009.Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360:2516–2527.
6. Bolla, M., G. Van Tienhoven, P. Warde, J. B. Dubois, R. O. Mirimanoff, G. Storme, et al. 2010. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 11:1066–1073.
7. Hanks, G. E., T. F. Pajak, A. Porter, D. Grignon, H. Brereton, V. Venkatesan, et al. 2003. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol.21:3972–3978.
8. Xie, D., C. Gore, J. Zhou, R.-C. Pong, H. Zhang, L. Yu, et al. 2009. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc. Natl Acad. Sci. 106:19878–19883.
9. Kong, Z., D. Xie, T. Boike, P. Raghavan, S. Burma, D. J. Chen, et al. 2010. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res.70:2829–2839.
10. Yu, L., V. Tumati, S. F. Tseng, F. M. Hsu, D. N. Kim, D. Hong, et al. 2012. DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor. Neoplasia14:1203–1212.
11. Tumati, V., S. Mathur, K. Song, J. Hsieh, D. Zhao, M. Takahashi, et al. 2013. Development of a locally advanced orthotopic prostate tumor model in rats for assessment of combined modality therapy. Int. J. Oncol. 42:1613–1619.
12. Duggan, D., S. L. Zheng, M. Knowlton, D. Benitez, L. Dimitrov, F. Wiklund, et al. 2007. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl Cancer Inst. 99:1836–1844.
13. Jacobs, C., V. Tumati, P. Kapur, J. Yan, D. Hong, M. Bhuiyan, et al. 2014. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 89:729–735.
14. Zhang, T., Y. Shen, Y. Chen, J.-T. Hsieh, and Z. Kong. 2015. The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect. Int. J. Radiat. Biol. 91:368–378.
15. Xie, D., C. Gore, J. Liu, R.-C. Pong, R. Mason, G. Hao, et al. 2010. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc. Natl Acad. Sci. 107:2485–2490.
16. Wu, K., J. Liu, S. F. Tseng, C. Gore, Z. Ning, N. Sharifi, et al. 2014. The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene 33:1954–1963.
17. Chen, H., S. Toyooka, A. F. Gazdar, and J. T. Hsieh. 2003. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J. Biol. Chem. 278:3121–3130.
18. Chen, H., R.-C. Pong, Z. Wang, and J.-T. Hsieh. 2002. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 79:573–581.
19. Dote, H., S. Toyooka, K. Tsukuda, M. Yano, M. Ouchida, H. Doihara, et al. 2004. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin. Cancer Res.10:2082–2089.
20. Qiu, G.-H., H. Xie, N. Wheelhouse, D. Harrison, G. G. Chen, M. Salto-Tellez, et al. 2007. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J. Hepatol. 46:655–663.
21. Yano, M., S. Toyooka, K. Tsukuda, H. Dote, M. Ouchida, T. Hanabata, et al. 2005. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int. J. Cancer 113:59–66.
22. Dote, H., S. Toyooka, K. Tsukuda, M. Yano, T. Ota, M. Murakami, et al. 2005. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br. J. Cancer 92:1117–1125.
23. Tsai, Y.-S., C.-L. L. Lai, C.-H. Lai, K.-H. Chang, K. Wu, S.-F. Tseng, et al. 2014. The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget5:6425–6436.
24. Shen, Y.-J., Z.-L. Kong, F.-N. Wan, H.-K. Wang, X.-J. Bian, H.-L. Gan, et al. 2014. Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. Cancer Sci. 105:704–712.
25. Zhu, J. N., K. J. Wu, Z. F. Guan, L. X. Liu, Z. Y. Ning, J. C. Zhou, et al. 2014. DAB2IP expression in bladder transitional cell carcinoma and its correlation with clinical outcome. J. Sichuan Univ. Med. Sci. Edition45:591–594.
26. Calvisi, D. F., S. Ladu, E. A. Conner, D. Seo, J.-T. Hsieh, V. M. Factor, et al. 2011. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J. Hepatol.54:311–319.
27. Chen, H., S. W. Tu, and J. T. Hsieh. 2005. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J. Biol. Chem. 280:22437–22444.
28. Rhodes, D. R., M. G. Sanda, A. P. Otte, A. M. Chinnaiyan, and M. A. Rubin. 2003. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J. Natl Cancer Inst. 95:661–668.
29. Varambally, S., S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda, et al. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629.
30. Wang, Z., C.-P. Tseng, R.-C. Pong, H. Chen, J. D. McConnell, N. Navone, et al. 2002. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer: characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J. Biol. Chem. 277:12622–12631.
31. Roach, M., G. Hanks, H. Thames, P. Schellhammer, W. U. Shipley, G. H. Sokol, et al. 2006. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65:965–974.
32. Kong, Z., P. Raghavan, D. Xie, T. Boike, S. Burma, D. Chen, et al. 2010. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 78:1210–1218.
33. Wu, K., D. Xie, Y. Zou, T. Zhang, R.-C. Pong, G. Xiao, et al. 2013. The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin. Cancer Res. 19:4740–4749.
34. Yang, L., Y. Li, X. Ling, L. Liu, B. Liu, K. Xu, et al. 2011. A common genetic variant (97906C>A) of DAB2IP/AIP1 is associated with an increased risk and early onset of lung cancer in chinese males. PLoS ONE 6:e26944.
35. Xu, S., Y. Zhou, W.-D. Du, G. Chen, F.-S. Zhou, M. Schneider, et al. 2013. Association of the variant rs2243421 of human DOC-2/DAB2 interactive protein gene (hDAB2IP) with gastric cancer in the Chinese Han population. Gene 515:200–204.
36. Conway, K., S. N. Edmiston, R. May, P. F. Kuan, H. Chu, C. Bryant, et al. 2014. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. Breast Cancer Res. 16:450.
37. Lai, C.-H., C.-S. Chang, H.-H. Liu, Y.-S. Tsai, F.-M. Hsu, Y.-L. Yu, et al. 2014. Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin. Oncotarget 5:5523–5534.
38. Zhou, W., J. Wang, W. Y. Man, Q. W. Zhang, and W. G. Xu. 2015. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells. Asian Pac. J. Cancer Prev. 16:2425–2430.